Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Summary

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease \[no response or response lasting less than 6 months at any previous line of treatment\] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib.

Timeline

Start

2019-10-18

Primary completion

2021-04-29

Completion

2023-05-10

Drugs

Indications